Abstract. TP53-regulated inhibitor of apoptosis 1 (TRIAP1) is a novel apoptosis inhibitor that binds HSP70 in the cytoplasm and blocks the formation of the apoptosome and caspase-9 activation. TRIAP1 has been shown to be upregulated in many types of cancers; however, its role remains elusive. We determined the TRIAP1 mRNA levels in a panel of human tissues and found its expression to be ubiquitous. Normal breast, as well as non-tumorigenic breast cells, exhibited lower TRIAP1 mRNA levels than breast cancer cells or their drug-resistant derivatives. TRIAP1 is a small, evolutionarily conserved protein that is 76 amino acids long. We found that yeast cells, in which the TRIAP1 homologue was knocked out, had increased sensitivity to doxorubicin. Equally, RNA interference in breast cancer drug-resistant cells demonstrated that downregulation of TRIAP1 impaired cell growth in the presence of doxorubicin. As expected, caspase-9 activation was diminished after overexpression of TRIAP1 in drug-resistant cells. Importantly, stable transfections of a TRIAP1 expression plasmid in CAL51 cells led to a marked increase in the number of doxorubicin-resistant clones, that was abolished when cells expressed hairpins targeting TRIAP1. In addition, we showed that TRIAP1 expression was also triggered by estrogen deprivation in MCF-7 cells. Although both polyclonal and monoclonal antibodies generated for the present study failed to robustly detect TRIAP1, we demonstrated that TRIAP1 represents a novel marker for drug resistance in breast cancer cells and it may be used in the stratification of breast cancer patients once a suitable antibody has been developed. Equally, these studies open potential drug development strategies for blocking TRIAP1 activity and avoiding drug resistance.
Introduction
One of the many mechanisms by which cancer cells acquire drug resistance is by apoptosis evasion (1, 2) . Antineoplastic agents activate the apoptotic intrinsic pathway which results in the permeabilization of the outer mitochondrial membrane. The subsequent release of cytochrome c and other pro-apoptotic molecules leads to the formation of a large protein complex, the apoptosome, containing cytochrome c, apoptotic protease activating factor 1 (Apaf-1) and caspase-9. Regulation of these processes occurs through the activity of members of the BCL-2 family of proteins (3) . Upregulation of anti-apoptotic proteins, such as BCL-2, BCL-XL, and members of the inhibitor of apoptosis (IAP) family, and inactivating mutations in pro-apoptotic proteins Bax and Bak, or p53 have been described in both the development of cancer and drug resistance (2, 4) . Among several therapeutic strategies, the restoration of p53-mediated apoptosis in cancer cells has been sought for some time, so far without a clinical application (5, 6) . Therefore, targeting inhibitors of apoptosis offer another opportunity for drug development (7) .
TP53-regulated inhibitor of apoptosis 1 (TRIAP1; alias p53CSV, p53-inducible cell-survival factor) is a small, evolutionarily conserved protein that is 76 amino acids long and contains a twin Cx 9 C motif. Its expression is induced by p53 following low levels of genotoxic stress (8) . In yeast it is located in the mitochondrial intermembrane space where it can interact with both Ups1 and Ups2, protecting them against proteolysis and regulating cardiolipin and phosphatidylethanolamine levels within mitochondria (9) . In its extramitochondrial role, TRIAP1 modulates apoptotic pathways through interaction with HSP70, inhibition of the interaction of cytochrome c with Apaf-1 and activation of caspase-9, to inhibit apoptosis and permit DNA damage repair (8, 10 does not share any similarity with XIAP, c-IAP, survivin or other members of the IAP family (11) . TRIAP1 is upregulated in myelomas with unfavorable prognosis (12) and TRIAP1 mRNA has been found in all breast cancer cell lines tested (13) . However, the role of TRIAP1 in breast or other solid tumors has been poorly addressed. Breast cancer is one of the most common tumors affecting women, and chemotherapy, endocrine therapy and radiotherapy regimens are part of the present mainstream treatment. Even those cancers that initially respond well to treatment may become resistant and give rise to secondary tumors, normally with fatal consequences (14) . Thus, it is crucial to be able to predict which patients will respond to therapy in order to design the best clinical strategy available and to develop drugs for the treatment of resistance (15) .
Here we describe the upregulation of TRIAP1 in drug-resistant breast cancer cells. Experimental modulation of TRIAP1 in breast cancer cells, either by overexpression or downregulation by RNA interference, changed cellular sensitivity to doxorubicin, thus confirming TRIAP1 as a novel effector of drug resistance.
Materials and methods
Cell culture, transduction and transfection. The breast cancer cell lines CAL51 (German Resource Centre for Biological Material, DSMz, Braunschweig, Germany) and MCF7 (European Collection of Cell Cultures, Health Protection Agency, UK) were grown in low glucose (1 g/l) Dulbecco's modified Eagle's medium (DMEM)-GlutaMax (Invitrogen, Carlsbad, CA, USA) supplemented with 10% foetal calf serum (FCS). Drug-resistant derivatives CALDOX, MCFDOX and MLET5 have been previously described (16) (17) (18) . RNA from MDA-MB-231, T47D, zR75 and 226-L-U19 cells (19) was a generous gift from Y. zhou. Human primary mammary epithelial cells (HMECs) were purchased from Invitrogen and immortalized by expression of the catalytic subunit of human telomerase as previously described (20) to generate HMEC-TERT cells. HMECs were grown on Mammary Epithelial Cell Growth Medium (Invitrogen). GP2-293 pantropic retroviral packaging (Clontech Laboratories, Mountain View, CA, USA) and HEK293T cells (American Type Culture Collection, LGC Standards, Teddington, UK) were maintained in DMEM supplemented with 4.5 g/l glucose, 10% FCS and 4 mM L-glutamine (Invitrogen). For culturing in estrogen-free conditions, MCF-7 cells were cultured in DMEM lacking phenol red (DMEM-PR; Gibco-BRL, UK), supplemented with 10% dextran-coated charcoal-stripped FCS (DSS; First Link Ltd., UK). MLET5 cells were routinely cultured in DMEM-PR, containing 10% DSS. All cells were routinely tested for the presence of mycoplasma using the Lonza MycoAlert kit (Basel, Switzerland).
DNA procedures.
A human TRIAP1 cDNA clone with a C-terminal GFP tag cloned into pCMV6-AC-GFP was purchased from Origene and used for transient transfections. For stable transfections, the genomic region encompassing TRIAP1 (first and second exons including both 5'-and 3'-UTRs as well as the single intervening sequence) was amplified from genomic DNA isolated from IMR-90 fibroblasts by PCR using Platinum ® Taq DNA Polymerase High Fidelity (Invitrogen) with primers OLEY335 and OLEY336 (Table Ι) . The amplified 2.6-kbp fragment was initially cloned into pCRII-TOPO (Invitrogen) and the TRIAP1 open reading frame verified by sequencing. Then, the genomic TRIAP1 fragment was liberated by digestion with BamHI and EcoRI and cloned into the BamHI-and EcoRI-digested lentiviral vector FUW. Retroviral plasmids pGFP-V-RS expressing short hairpins targeting TRIAP1 (5'-AGAGATTCCTATTGAAGGACTGG AGTTCA-3') and non-targeting scrambled (TR30013) were from Origene.
Viral transduction. Viral transductions were essentially as previously described (16) . Briefly, retroviral transfections were performed using 20 µg retroviral plasmid, 2 µg pVSV-G (Clontech Laboratories) and 55 µg Polyethylenimine (MW 25,000) (Polysciences, Warrington, PA, USA) prior to co-transfection into the GP2-293 pantropic retroviral packaging cells. Lentiviral transfections were performed using 20 µg lentiviral plasmid, 2 µg pVSV-G, 8 µg pPAX2 (Addgene, Cambridge, MA, USA) and 75 µg Polyethylenimine (MW 25,000) (SigmaAldrich, St. Louis, MO, USA) prior to co-transfection into the HEK293T cells. Viral supernatants were collected 24-48 h after transfections, filtered through 0.45-µm cellulose acetate filters and supplemented with 8 µg/ml Polybrene (SigmaAldrich) prior to adding to recipient cells. Puromycin (1 µg/ ml; Sigma-Aldrich) was added 96 h after the first infection to recipient cells for selection of stable transgene expression.
Transient transfections. Cells (1x10 5 in 6-well plates) were transfected with a final concentration of 40 nM ON-TARGETplus SMARTpool TRIAP1 siRNA oligonucleotides (Thermo Scientific) using HiPerFect (Qiagen, UK) following the manufacturer's instructions. EGFP siRNA (Ambion, UK) was used as a negative control (21) . A sulphorhodamine B (Sigma-Aldrich) assay (22) was used to screen for drug cytotoxicity as previously described (19) . For transient overexpression, cells (1x10 4 ) were seeded in 96-well plates and transfected with FuGENE HD (Promega, Madison, WI, USA) using 2 µg DNA as recommended by the manufacturer. Then cells were treated for 24 h with 0.4 µM doxorubicin, and caspase-9 activity was determined using a Caspase-Glo 9 assay (Promega) following the manufacturer's instructions and normalized to cell density obtained after sulphorhodamine B staining.
Gene expression analysis. Total RNA (isolated using RNAzol B; Biogenesis, Poole, UK) was reverse transcribed with RNase H + MMLV Reverse Transcriptase (iScript cDNA Synthesis kit; Bio-Rad) and real-time quantitative PCR was performed using SYBR-Green (Bioline Reagents, London, UK) and gene specific primers (Table I) on an ABI Prism 7700 Detection system (PerkinElmer Life Sciences, Waltham, MA, USA). PCR conditions included an initial step at 95˚C for 10 min followed by 40 cycles of 95˚C for 30 sec, 60˚C for 30 sec and 72˚C for 30 sec. A comparative threshold cycle was used to determine the relative gene expression as previously described (23) . TFF1 expression was performed using TaqMan Gene Expression assay Hs00907239_m1 (Invitrogen) following the manufacturer's instructions.
Yeast procedures. Wild-type Saccharomyces cerevisiae BY4743 (MATa/α his3Δ1/his3Δ1 leu2Δ0/leu2Δ0 met15Δ0/ MET15 lys2Δ0/LYS2 ura3Δ0/ura3Δ0) and Mdm35 knockout strain were purchased from Open Biosystems. Screening for drug toxicity was performed in YPD plates with doxorubicin after 3 days of growth.
Drug resistance clonogenic assay. Cells were seeded, at least in duplicate, at a density of 1-5x10 5 cells in 25-cm 2 culture flasks and exposed to a single dose of doxorubicin for 24 h. Cells were kept in culture for 2-4 weeks with drug-free medium changes every week. Drug-resistant clones were fixed with 4% paraformaldehyde and stained with 0.2% crystal violet. Crystal violet retained in the cells was quantified by solubilization with 33% acetic acid and measured at OD 592 nm.
Statistical analysis. Statistical evaluations were performed using the Student's t-test for paired data, and data were considered significant at a P-value <0.05.
Results

TRIAP1 is ubiquitously expressed in normal human tissues and upregulated in breast cancer cells.
We initially tested TRIAP1 expression in a panel of RNAs from normal human tissues (24) and found it ubiquitously expressed (Fig. 1A) . Although there was a lack of tissue specificity, bone marrow, heart and kidney showed very low expression, whereas brain, placenta and testis showed high expression, with that from skeletal muscle being the highest. Normal breast tissue expressed TRIAP1 mRNA at intermediate levels (Fig. 1A) . Next we tested TRIAP1 mRNA expression in four breast cancer cell lines (CAL51, MDA-MB-231, T47D and zR75) and in two immortal, but non-tumorigenic, breast cell lines (HMEC-TERT and 226-L-U19). An ~2-fold upregulation was found in the cancerous cell lines, indicating that malignant transformation of breast epithelial cells is, at least in vitro, associated with TRIAP1 upregulation (Fig. 1B) .
A polyclonal antibody raised to the synthetic peptide CVQKAIKEKEIPIEGLEF (amino acids 47-64) as well as three monoclonal antibodies raised to the epitopes HGKEKPENSS (amino acids 67-76), IKEKEIPIEG (amino acids 52-61) and FAEKFLKGDS (amino acids 23-32), all failed to robustly detect TRIAP1 as a band at ~10 kDa (data not shown). Equally, a few commercial antibodies were tested and failed in the same way (data not shown). Thus, TRIAP1 expression analyses throughout the present study were performed exclusively at the mRNA level.
TRIAP1 is upregulated in drug-resistant breast cancer cell lines. TRIAP1 upregulation following genotoxic stress has been exclusively demonstrated in a colon cancer cell line (8) . We confirmed that CAL51 breast cancer cells exhibited upregulation of TRIAP1 mRNA expression after 24 h of doxorubicin treatment at low to moderate doses (up to 0.4 µM). Higher doses (2-5 µM) repressed TRIAP1 expression (Fig. 1C) . Then we examined whether TRIAP1 was associated with a drugresistance phenotype. For this, we tested TRIAP1 mRNA expression in two doxorubicin-resistant breast cancer cell lines derived from CAL51 (16) and MCF7 (17) cells, and in a third cell line derived from MCF7 cells after estrogen deprivation, which are resistant to tamoxifen and etoposide (18) . Doxorubicin and etoposide are two topoisomerase II inhibitors producing genotoxic stress, ultimately leading to apoptosis, which form part of many chemotherapeutic cancer regimes. TRIAP1 mRNA was upregulated in these three drug-resistant cell types between 3-and 8-fold (Fig. 1D) .
TRIAP1 is an effector of drug resistance. In order to determine whether TRIAP1 is an effector of drug resistance, we tested cell susceptibility to doxorubicin after experimental modulation of TRIAP1 expression. Comparison of TRIAP1 protein sequences revealed a striking conservation across kingdoms ( Fig. 2A) , albeit not at the C-terminus, indicating that this protein must perform a fundamental role in cellular physiology. The TRIAP1 homologue in S. cerevisiae, Mdm35, shares 33% identity with human TRIAP1. Since yeast cells harbour an ancestral programmed cell death machinery that shares many key molecules that are part of the apoptotic intrinsic pathway in mammalian cells (25) , and because genetic manipulation of yeast allows the knockout of genes, we initially tested our hypothesis in Mdm35 knockout yeast cells. Indeed, ΔMdm35 cell growth was greatly inhibited by the presence of doxorubicin in the yeast growth medium compared to wild-type cell growth (Fig. 2B) .
Next, we determined whether experimental downregulation of TRIAP1 would have a similar effect in breast cancer cells. For this, we transiently transfected siRNAs targeting TRIAP1 (Fig. 3A) . Transfection of siRNAs targeting EGFP mRNA, which is not expressed in these cells, was used as a negative control. This transient decrease in TRIAP1 mRNA levels was sufficient to inhibit the proliferation of cells in the presence of doxorubicin compared to the slight decrease in proliferation obtained with the negative control (Fig. 3B) . As TRIAP1 blocks the formation of the apoptosome and activation of caspase-9 (8), we next ascertained whether caspase-9 activity would be reduced by TRIAP1 in breast cancer cells. To do this, we transiently overexpressed TRIAP1 in CAL51 cells (Fig. 3C ) and treated them with 0.4 µM doxorubicin for 24 h. As expected, the control cells transfected with an empty vector exhibited increased caspase-9 activity, and this increase was reduced in the cells overexpressing TRIAP1 (Fig. 3D) .
Although experiments performed with transient transfections are informative to assess the short-term susceptibility to cytotoxic drugs, the generation of drug resistance is a slower process, often taking several weeks in vitro, and required a different approach. We generated CAL51 derivative cells that had either permanently downregulated TRIAP1 by stable expression of hairpins targeting TRIAP1 mRNA (shTRIAP) or permanently upregulated TRIAP1. CAL-shTRIAP cells showed decreased levels of TRIAP1 mRNA by ~60% (Fig. 4A) . In addition, we managed to reproduce the slight increase in TRIAP1 mRNA expression found in drug-resistant CALDOX cells by using low multiplicity of infection of the lentivirus used for TRIAP1 overexpression (Fig. 4A) . Thus, although these experimental changes in TRIAP1 expression after stable gene expression were modest, they reflect very accurately the difference found between naïve and drug-resistant cells (Fig. 1D) . Next we performed clonogenic assays after doxorubicin treatment. For this, doxorubicin was added to cell cultures and the emergence of doxorubicin-resistant clones was monitored over a period of 2-4 weeks. Stable experimental overexpression of TRIAP1 led to an increase in doxorubicin-resistant clones, and, conversely, downregulation of TRIAP1 led to fewer drug-resistant clones than the control cells ( Fig. 4B and C) .
TRIAP1 is upregulated by lack of estrogen. As tamoxifen-resistant cells have elevated levels of TRIAP1 mRNA (Fig. 1D) , we investigated whether a link exists between estrogen and TRIAP1 expression. We cultured MCF-7 and MLET5 cells for 3 days in estrogen-deprived medium, re-introduced estrogen for 16 h, and then determined TRIAP1 mRNA levels. There was no upregulation of TRIAP1 in any cell type; in fact, MCF-7 cells treated with 10 nM estrogen showed a slight decrease in TRIAP1 expression (Fig. 5A) . As expected, the estrogen-responsive gene TFF1 (26) was upregulated in both cell lines (Fig. 5A ). This indicates that TRIAP1 is not an estrogen-responsive gene. Importantly, when MCF-7 cells were cultured in the absence of estrogen, TRIAP1 expression was upregulated (Fig. 5B) . Moreover, the addition of tamoxifen, which blocks estrogen receptor activation, led to a small but significant upregulation of TRIAP1 mRNA in the MCF-7 cells, but not, as expected, in the tamoxifen resistant MLET5 cells (Fig. 5C) .
Overall, these results establish TRIAP1 as a novel effector of drug resistance in breast cancer cells.
Discussion
One of the many mechanisms by which cancer cells develop resistance to therapeutic intervention is by apoptosis evasion. This is not surprising since the apoptotic machine is complex, with multiple layers of regulation (1, 2) . The IAP gene family encodes a group of structurally-related proteins sharing a BIR domain, such as XIAP or survivin, which can be upregulated in breast cancer (27, 28) . However, other inhibitors of apoptosis do not share structural similarities with members of the IAP family. One such protein, TRIAP1, is a small, 76-amino acid protein in humans that binds to HSP70 and inhibits the formation of the apoptosome. Apoptosis evasion is one of the hallmarks of cancer (29), and is thus not surprising to find TRIAP1 mRNA upregulated in a variety of malignancies (30) (31) (32) and in breast cancer cell lines, but not in TERT-immortalized primary mammary epithelial cells or in cells transformed but not yet fully tumorigenic (Fig. 1B) . Although the mechanisms upregulating TRIAP1 during tumorigenesis are not known, a low to moderate amount of several genotoxic agents triggers its expression via p53 activation (8) . Importantly we also found that estrogen deprivation upregulated TRIAP1. Estrogen deprivation reduces p53 activity (33, 34) , and in normal mammary epithelial cells tamoxifen activates p53 (35) , although not in MCF-7 cells (36) . Thus, the upregulation of TRIAP1 in these cases is very likely to be p53-independent. Our data clearly demonstrated that TRIAP1 is a novel effector of drug resistance. Its experimental overexpression confers cells the capacity to develop doxorubicin-resistant derivatives, whereas its downregulation by RNA interference generates cells more susceptible to the cytotoxic effects of the drug. Due to its ubiquitous tissue expression in humans and extremely high conservation throughout evolution it is likely that TRIAP1 has an important function in eukaryotic cells. Research on yeast indicates that TRIAP1 (Mdm35) normally resides in the mitochondrial intermembrane space where it interacts with Usp1 and Usp2 (PRELI1 and PRELI2 in humans) to regulate the synthesis of cardiolipin and phosphatidylethanolamine, respectively (9) . Although TRIAP1/PRELI complexes (Mdm35/Usp homologues in yeast) have been shown to prevent apoptosis by mediating intramitochondrial transport of phosphatidic acid in HeLa cells (37) , it is tempting to speculate that the upregulation of TRIAP1 expression following moderate genotoxic stress (Fig. 1C) , or that found in drug-resistant cells (Fig. 1D) , helps to maintain the balance towards apoptosis inhibition by blocking apoptosome formation and caspase-9 inactivation (8). However, after stronger genotoxic stress, which probably leads to irreparable DNA damage, there is no activation of TRIAP1 expression. A large escape of cytochrome c from the mitochondria would be enough to change the balance towards apoptosome formation and the background levels of TRIAP1 protein would not be enough to block the interaction cytochrome c-Apaf1-caspase-9 (38) . In addition, it is not clear whether, in addition to cytochrome c, TRIAP1 or TRIAP1/ PRELID complexes can also escape from the intermembrane space following stress to interact with HSP70. Nonetheless, yeast data as well as those presented here indicate a dual role for TRIAP1 in mitochondrial lipid biosynthesis and drug resistance. This may offer a potential drug development strategy for the synthesis of compounds blocking TRIAP1 activity. 
